EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Neonatal magnesium sulphate for neuroprotection: A systematic review and meta‐analysis

Emily Shepherd iD, Tasneem Karim, Sarah McIntyre iD, Shona Goldsmith iD, Amy Keir, Nadia Badawi, Rod W Hunt iD, Robert Galinsky

Developmental Medicine & Child Neurology · 2024

DOI: 10.1111/dmcn.15899 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Developmental Medicine & Child Neurology, 2024. Verfasst von Emily Shepherd und 7 weiteren Autor:innen. Beteiligte Einrichtung: Women and Kids Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia. Hauptthemen laut MEDLINE: Magnesium Sulfate, Neuroprotective Agents, Asphyxia Neonatorum, Hypoxia-Ischemia, Brain. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, Australia, National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To review the evidence of the effects of neonatal magnesium sulphate for neuroprotection in perinatal asphyxia and hypoxic‐ischaemic encephalopathy (HIE).

Method

This was a systematic review of randomized controlled trials (RCTs) (with meta‐analysis) and non‐RCTs assessing magnesium sulphate for treating perinatal asphyxia and HIE at 35 weeks or more gestation (primary outcomes: neonatal death and death or long‐term major neurodevelopmental disability).

Results

Twenty‐five RCTs (2099 infants) and four non‐RCTs (871 infants) were included, 23 in low‐ and middle‐income countries (LMICs). In RCTs, reductions in neonatal death with magnesium sulphate versus placebo or no treatment (risk ratio [RR] = 0.68; 95% confidence interval [CI] = 0.53–0.86; 13 RCTs), and magnesium sulphate with melatonin versus melatonin alone (RR = 0.74; 95% CI = 0.58–0.95; one RCT) were observed. No difference in neonatal death was seen for magnesium sulphate with therapeutic hypothermia versus therapeutic hypothermia alone (RR = 0.66, 95% CI = 0.34–1.26; three RCTs), or magnesium sulphate versus phenobarbital (RR = 3.00; 95% CI = 0.86–10.46; one RCT). No reduction in death or long‐term neurodevelopmental disability (RR = 0.52; 95% CI = 0.14–1.89; one RCT) but reductions in several short‐term adverse outcomes were observed with magnesium sulphate. Evidence was low‐ to very‐low certainty because of risk of bias and imprecision.

Interpretation

Given the uncertainty of the current evidence, further robust neonatal magnesium sulphate research is justified. This may include high‐quality studies to determine stand‐alone effects in LMICs and effects with and after therapeutic hypothermia in high‐income countries.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Magnesium SulfateNeuroprotective AgentsAsphyxia NeonatorumHypoxia-Ischemia, BrainHumansInfant, NewbornRandomized Controlled Trials as TopicHypothermia, Induced

Substanzen

Magnesium SulfateNeuroprotective Agents

Autor:innen und Institutionen

  • Women and Kids Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.
  • Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia.
  • Cerebral Palsy Alliance Research Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
  • Grace Centre for Newborn Intensive Care, The Children's Hospital, Sydney, New South Wales, Australia.
  • Department of Paediatrics, Monash University, Melbourne, Victoria, Australia.
  • Monash Newborn, Monash Children's Hospital, Melbourne, Victoria, Australia.

ORCID-Profile: Emily Shepherd, Sarah McIntyre, Shona Goldsmith, Rod W Hunt

Förderung

  • National Health and Medical Research Council, Australia
  • National Health and Medical Research Council

Zitieren

APA

Shepherd, E., Karim, T., McIntyre, S., Goldsmith, S., Keir, A., Badawi, N., Hunt, R. W., & Galinsky, R. (2024). Neonatal magnesium sulphate for neuroprotection: A systematic review and meta‐analysis. Developmental Medicine & Child Neurology. https://doi.org/10.1111/dmcn.15899

Vancouver

Shepherd E, Karim T, McIntyre S, Goldsmith S, Keir A, Badawi N, et al. Neonatal magnesium sulphate for neuroprotection: A systematic review and meta‐analysis. Developmental Medicine & Child Neurology. 2024. doi:10.1111/dmcn.15899

BibTeX
@article{Shepherd2024,
  author = {Shepherd, Emily and Karim, Tasneem and McIntyre, Sarah and Goldsmith, Shona and Keir, Amy and Badawi, Nadia and Hunt, Rod W and Galinsky, Robert},
  title = {Neonatal magnesium sulphate for neuroprotection: A systematic review and meta‐analysis},
  journal = {Developmental Medicine & Child Neurology},
  year = {2024},
  doi = {10.1111/dmcn.15899}
}
Kostenlos starten →